% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stoian:168703,
      author       = {R. Stoian$^*$ and T. Erbes and C. Zamboglou$^*$ and J.
                      Scholber$^*$ and M. Gainey$^*$ and I. Sachpazidis$^*$ and E.
                      Haehl$^*$ and S. K. B. Spohn$^*$ and V. Verma and D. Krug
                      and A. Rühle$^*$ and I. Juhasz-Böss and A.-L. Grosu$^*$
                      and N. H. Nicolay$^*$ and T. Sprave$^*$},
      title        = {{I}ntraoperative radiotherapy boost as part of
                      breast-conservation therapy for breast cancer: a
                      single-institution retrospective analysis.},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {197},
      number       = {9},
      issn         = {1439-099X},
      address      = {Heidelberg},
      publisher    = {Springer Medizin},
      reportid     = {DKFZ-2021-01011},
      pages        = {812-819},
      year         = {2021},
      note         = {2021 Sep;197(9):812-819},
      abstract     = {There are currently no data from randomized controlled
                      trials on the use of intraoperative radiotherapy (IORT) as
                      a tumor bed boost as part of a breast-conservation
                      approach for breast cancer. This study retrospectively
                      reviewed the safety and efficacy of IORT as a boost
                      treatment at a tertiary cancer center.From 2015 to 2019,
                      patients underwent breast-conserving surgery with axillary
                      lymph node staging and a single dose of 20 Gy IORT with
                      50-kV photons, followed by whole-breast irradiation (WBI)
                      and adjuvant systemic therapy (if applicable). Patients were
                      followed for assessment of acute and late toxicities (using
                      the Common Terminology Criteria for Adverse Events version
                      5.0) at 3-6-month intervals. Outcomes included ipsilateral
                      (IBTR) and contralateral breast progression-free survival
                      (CBE), distant metastasis-free survival (DMFS), and overall
                      survival (OS).Median follow-up for the 214 patients was 28
                      (range 2-59) months. Most patients had T1 disease (n = 124)
                      and were clinically node negative. Only few patients had
                      high-grade and/or triple-negative disease. The vast majority
                      of patients underwent sentinel node biopsy, and 32 $(15\%)$
                      required re-resection for initially positive margins.
                      Finally, all tumor bed margins were clear. Nine $(4.2\%)$
                      and 48 $(22.4\%)$ patients underwent neoadjuvant and
                      adjuvant chemotherapy, respectively. WBI was predominantly
                      performed as conventionally fractionated WBI (n = 187,
                      $87.4\%),$ and the median time from BCS to WBI was
                      54.5 days. IORT was delivered with a single dose of 20 Gy.
                      The median WBI dose was 50 Gy (range 29.4-50.4 Gy). No
                      patients experienced grade 4 events; acute grade 3
                      toxicities were limited to 17 $(8\%)$ cases of radiation
                      dermatitis. Postoperative toxicities were mild. After WBI
                      only one case of late grade ≥ 2 events was reported. There
                      were two recurrences in the tumor bed and one contralateral
                      breast event.This investigation provides additional
                      preliminary data supporting the using of IORT in the boost
                      setting and corroborates the existing literature. These
                      encouraging results should be prospectively validated by the
                      eventual publication of randomized studies such as
                      TARGIT‑B.},
      keywords     = {Adjuvant radiation therapy (Other) / Boost (Other) /
                      Breast-conservation therapy (Other) / Early breast cancer
                      (Other) / Intraoperative radiotherapy (Other)},
      cin          = {FR01 / E055},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331 / I:(DE-He78)E055-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33938966},
      doi          = {10.1007/s00066-021-01785-2},
      url          = {https://inrepo02.dkfz.de/record/168703},
}